Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

B cell populations: the multiple myeloma model

F Caligaris-Cappio1, M G Gregoretti, K Nilsson

  • 1Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Italy. Caligari@golgi.molinette.unito.it

Chemical Immunology
|January 1, 1997
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Leukemia·2017
Same author

B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.

Leukemia·2016
Same author

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.

Leukemia·2012
Same author

The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.

Leukemia·2011
Same author

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Lancet (London, England)·2010